Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 187

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 187
---
 market valuations of similar companies; 

•announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; 

•changes in financial estimates by the Company or by any securities analysts who might cover our stock; 

•fluctuation of the market values of any of our potential strategic investments; 

•issuances of debt or equity securities; 

•compliance with our contractual obligations; 

•sales of our Common Stock by us or our stockholders in the future; 

•trading volume of our Common Stock; 

•ineffectiveness of our internal controls; 

•publication of research reports about the Company or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;

•general political and economic conditions, including the wars in Ukraine and Israel; 

•effects of natural or man-made catastrophic events; 

•effects of public health crises, pandemics and epidemics; and 

•other events or factors, many of which are beyond our control, such as the government closure of Silicon Valley Bank and Signature Bank, and liquidity concerns at other financial institutions.

Further, the global equity markets in general have recently experienced extreme price and volume fluctuations, including as a result of the COVID-19 pandemic, economic uncertainty and increased interest rates, inflation, the government closure of Silicon Valley Bank 

 105

and Signature Bank, and liquidity concerns at other financial institutions that may be unrelated to our operating performance. Continued market fluctuations could result in extreme volatility in the price of our Common Stock, which could cause a decline in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against the Company, could cause us to incur substantial costs and divert management’s attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including those described in these “Risk Factors”, could have a dramatic and material adverse impact on the market price of our Common Stock. 

We have not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future and there is no assurance that we will complete the previously declared stock dividend. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock. 

We have not paid cash dividends on our